Does the COVID Vaccine Affect Prostate Cancer?

No large body of evidence shows that COVID-19 vaccines cause prostate cancer or make existing prostate cancer worse. One large Korean observational study did find a statistically higher rate of prostate cancer diagnoses in the year after vaccination, but that finding sits against a backdrop of pandemic-era screening disruptions, slight vaccine-related changes in a common blood test, and imaging artifacts that can mimic cancer spread. Disentangling these threads matters, because the question touches on real anxieties among men who are either being screened for prostate cancer or already living with a diagnosis.

The Korean Study That Made Headlines

The most striking data point in this conversation comes from a large retrospective study of over 8.4 million people in Seoul, South Korea. Researchers used national health insurance records from 2021 to 2023 and compared cancer rates between vaccinated and unvaccinated groups. The hazard ratio for prostate cancer one year after vaccination was roughly 1.69, meaning vaccinated men were diagnosed at a rate about 69 percent higher than unvaccinated men during the study window. The study also found elevated hazard ratios for thyroid, gastric, colorectal, lung, and breast cancers, suggesting the signal was not specific to the prostate.¹

A number that size is hard to ignore, but it is also hard to interpret at face value. Observational studies of this kind can capture genuine biological effects, or they can reflect who showed up for medical care and when. During 2021 and 2022, health systems worldwide saw massive shifts in who was visiting doctors and getting tested. Vaccinated individuals, as a group, tend to engage more with the healthcare system than unvaccinated individuals. That means cancers that were already growing may simply have been caught sooner and more frequently in the vaccinated group, not caused by the vaccine. The Korean study itself acknowledges confounding as a limitation, and its design cannot prove that the vaccines triggered new cancers rather than accelerated detection of existing ones.

Pandemic Screening Disruptions and Detection Bias

To understand why detection bias is such a plausible explanation, you need to see what happened to prostate cancer screening during the pandemic. In the United States, PSA testing dropped by about 36 percent during the early months of the pandemic, and prostate biopsies fell by nearly 38 percent. Even after healthcare reopened, biopsies remained roughly 18 percent below pre-pandemic levels, and the number of high-grade cancers diagnosed (Gleason score 8 or above) stayed about 12 percent below where it had been.²

Those missing diagnoses did not disappear. They accumulated. When men returned to screening, many of those cancers would have been found, creating a temporary wave of new diagnoses that coincided with the vaccination campaign. Vaccination itself often served as the reentry point into the healthcare system: a man who went to a pharmacy or clinic for his shot might also have resumed routine checkups, bloodwork, and cancer screening shortly afterward. An observational study comparing vaccinated and unvaccinated groups during this same window would naturally capture that wave of catch-up diagnoses in the vaccinated column.

An Italian cohort study tracking hospitalizations for cancer after vaccination took similar methodological precautions, excluding anyone who had already been hospitalized for that specific cancer in the previous ten years to focus on genuinely new cases.³ These design choices matter, but they still cannot fully account for the healthy-vaccinee effect or differences in healthcare engagement between groups.

What Happens to PSA After Vaccination

PSA, or prostate-specific antigen, is the blood marker most commonly used to screen for prostate cancer. Any factor that nudges PSA upward can trigger additional testing, biopsies, and anxiety, so understanding whether the COVID vaccine moves that needle is practical information.

A study looking specifically at this question found that PSA levels did rise slightly after vaccination. After one dose, the median increase was about 0.03 ng/mL; after three doses, it was about 0.09 ng/mL. Both changes were statistically significant but clinically tiny.⁴ To put that in perspective, PSA levels below 4.0 ng/mL are generally considered normal, and day-to-day fluctuations from things like exercise, sexual activity, or a urinary tract infection can easily cause shifts of 0.5 ng/mL or more.

So the vaccine can technically raise PSA, but the amount is unlikely to push an otherwise normal result over a clinical threshold. If you are in active surveillance for prostate cancer and tracking your PSA closely over time, it is worth mentioning to your urologist that you recently got a COVID shot, the same way you would mention a recent bike ride or any other factor that could cause a transient bump. But the vaccine is not going to manufacture a false cancer scare on its own through PSA alone.

How the Vaccine Can Fool Cancer Imaging

Where the vaccine does create a more visible problem is in imaging. PET/CT scans are used to look for cancer spread, and they work by highlighting areas of high metabolic activity. After a COVID vaccine, the lymph nodes near the injection site (typically in the armpit and above the collarbone on the same side) often light up on these scans because the immune system is actively responding. That response is completely normal and has nothing to do with cancer, but it can look exactly like a metastatic lymph node to a radiologist who is not aware of recent vaccination.

This is not a theoretical concern. One study found that roughly 43 percent of patients scanned with a tracer called 18F-fluorocholine showed positive vaccine-related lymph nodes, and about 13 percent of patients scanned with 68Ga-PSMA-11, a tracer commonly used for prostate cancer staging, showed the same pattern.⁵ Another group described the phenomenon specifically as a source of false positive cases in cancer imaging, noting that prostate cancer patients undergoing choline PET/CT were among those affected.⁶ Separately, vaccination-associated lymphadenopathy was seen on PSMA PET in about 45 percent of prostate cancer patients, though the signal dropped substantially after about eight weeks.⁷

The practical takeaway here is timing. If you have a PET/CT scan scheduled for prostate cancer staging or monitoring, your doctor should know exactly when you received your last COVID vaccine dose and which arm it went into. Waiting at least eight weeks after vaccination before a staging scan can reduce the chance of a confusing result. Nuclear medicine teams have increasingly built this into their protocols, but it is not universal, so bring it up yourself if your scan is coming up soon after a booster.

Safety for Men Already Being Treated for Prostate Cancer

Men who are receiving treatment for prostate cancer often worry about whether the vaccine is safe to get during therapy and whether it will actually work, given that some treatments suppress the immune system. The evidence on both counts is reassuring.

A study of prostate cancer patients on advanced hormonal therapies (abiraterone or enzalutamide) found no safety issues related to the combination of these drugs and COVID vaccination. Side effects were mild: about a quarter of patients had injection-site pain after the first dose, and a small fraction reported nausea or dizziness after the second.⁸ These are the same kinds of reactions seen in the general population.

A retrospective study of patients with advanced genitourinary cancers, including prostate cancer, found that vaccination was about 82 percent effective at preventing SARS-CoV-2 infection and roughly 86 percent effective at preventing hospitalization from COVID-19. Breakthrough infection rates were far lower in the vaccinated group compared to the unvaccinated group.⁹ Given that cancer patients face higher risks of severe COVID-19 outcomes, this is significant.

One area that does deserve attention involves chemotherapy with taxane drugs (like docetaxel, commonly used in metastatic prostate cancer). A study found that patients who had received a COVID-19 vaccine before their first taxane infusion had a higher rate of hypersensitivity reactions during the infusion, at about 12 percent compared to roughly 3 percent in patients who were unvaccinated or received the vaccine afterward. Reactions in the vaccinated group also tended to be more severe.¹⁰ This does not mean you should skip vaccination before chemo. It means your oncology team should be aware of the timing so they can monitor for reactions appropriately. The mRNA vaccines and the taxane drugs both use lipid-based delivery systems, and the leading hypothesis is that prior exposure to similar lipid components may prime the immune system to react more strongly to them later.

The Lipid Nanoparticle Question

Speaking of lipid nanoparticles, a mouse study published in 2025 found that the lipid nanoparticles used in mRNA vaccines, separate from the mRNA itself, could promote tumor metastasis in animals. The proposed mechanism involves the LNPs triggering an inflammatory response at the injection site, which releases mitochondrial DNA from damaged muscle cells. That DNA then activates immune pathways that cause neutrophils to form web-like structures in the lungs, which can create a more hospitable environment for circulating tumor cells to land and grow.¹¹

This is a legitimate area of basic science research, but it comes with major caveats. Mouse models of metastasis typically involve injecting large numbers of tumor cells directly into the bloodstream, which creates conditions far removed from how human cancer naturally spreads. The doses of LNPs relative to body size, the timing of injections, and the specific tumor cell lines used all limit how directly these findings translate to people. No human study has shown that mRNA vaccine LNPs promote metastasis. The finding raises questions worth investigating in human populations, but it does not, by itself, constitute evidence that COVID vaccines worsen cancer outcomes in people.

Pharmacovigilance Data Shows No Urologic Signal

One of the ways health authorities monitor vaccine safety after rollout is through adverse event reporting systems. In the United States, the Vaccine Adverse Event Reporting System (VAERS) collects reports from anyone, including patients, doctors, and manufacturers, about health problems that occur after vaccination. A large analysis of over 700,000 event reports related to COVID vaccines, containing nearly 3 million individual symptoms, looked specifically for urologic adverse events. The researchers compared these against a similar volume of reports for all other vaccines. No urologic symptom, including any related to the prostate, produced a disproportionate safety signal linked to COVID vaccination.¹²

VAERS data has real limitations. It captures short-term events better than long-term ones, it relies on voluntary reporting, and it cannot prove causation. But the absence of even a statistical signal across hundreds of thousands of reports is meaningful. If COVID vaccines were causing prostate problems at any appreciable rate, you would expect to see at least some clustering in this data. The silence is informative.

Why the Prostate Is Biologically Relevant to SARS-CoV-2

An entirely separate strand of research has explored why the prostate gland keeps showing up in COVID-related studies at all. The answer lies in the proteins the virus uses to enter human cells. SARS-CoV-2 binds to a receptor called ACE2 and relies on an enzyme called TMPRSS2 to gain entry. Both of these proteins are present in prostate tissue, and both are regulated by androgen (male hormone) signaling.¹³

Research has shown that the androgen receptor directly controls the expression of ACE2, TMPRSS2, and another co-receptor called FURIN. When androgen signaling is blocked, levels of these proteins drop. When androgens are added, the proteins go up, along with the ability of cells to internalize the virus’s spike protein.¹⁴ This is part of why men, on average, have experienced more severe COVID-19 than women, and why researchers initially speculated that androgen-deprivation therapy (a standard prostate cancer treatment) might offer some protection against the virus.

This biology does not mean the vaccine targets or harms the prostate. The vaccine teaches the immune system to recognize the spike protein; it does not deliver the virus itself, and the spike protein produced by vaccination is not entering prostate cells and replicating. But it does explain why studies keep investigating prostate-specific outcomes after both infection and vaccination. The prostate sits at an unusual intersection of viral biology and hormonal regulation that makes it a natural subject of scrutiny.

mRNA Vaccines Being Developed to Treat Prostate Cancer

In a somewhat ironic twist, the same mRNA technology used in COVID vaccines is being actively developed as a treatment for prostate cancer. A phase I/IIa trial tested an mRNA vaccine called CV9103, which encodes four prostate-cancer-associated antigens: PSA, PSCA, PSMA, and STEAP1. The idea is to train the immune system to attack prostate cancer cells the way a COVID vaccine trains it to attack the spike protein. In the trial, about 79 percent of evaluable patients developed an immune response directed against at least one of the antigens, and nearly half responded to multiple antigens. Among patients with metastatic disease, the estimated median overall survival was about 31 months.¹⁵

These therapeutic cancer vaccines are still experimental and work differently from the preventive COVID vaccines. A COVID vaccine presents one target (the spike protein) to prevent infection. A cancer vaccine presents tumor-associated targets to a patient who already has cancer, trying to ramp up an immune attack on established disease. The manufacturing platform is similar, but the clinical goals are fundamentally different. Still, the progress in therapeutic mRNA vaccines for prostate cancer means that the broader mRNA technology is being evaluated not as a threat to prostate health but as a potential tool for treating the disease. Several newer candidates have entered clinical trials since the COVID-era acceleration of mRNA manufacturing.